skip to Main Content

Redox-Responsive Nanoplatform for Codelivery of miR-519c and Gemcitabine for Pancreatic Cancer Therapy

Newsfeed image, light gray text on dark gray background
Most patients with pancreatic cancer are present with metastatic or inoperable disease, and therefore, systemic polychemotherapy remains the treatment of choice.

The median survival of patients with metastatic pancreatic cancer is still less than a year with either FOLFIRINOX or GEM and nab-paclitaxel (67). Therefore, safer and more effective combination of GEM and novel drugs further need to be developed particularly for older or less fit patients or those with significant comorbidities, who cannot tolerate intensive chemotherapy. Read more . . .

Back To Top